AI-powered search
Try Polaris, our new AI-powered search!

Is it appropriate to reduce the frequency of tralokinumab in patients who respond to the medication?

Featuring Tina Bhutani, MD, MAS |

CEO, Synergy Dermatology  
Associate Clinical Professor of Dermatology  
University of California, SF  
San Francisco, CA

| Published February 16, 2023